5170W-11: BMS Simplicity

CRC 11060: Studying Interventions for Managing Patients with Chronic Myeloid Leukemia in Chronic Phase I: The 5-Year Prospective Cohort Study (SIMPLICITY)

Type of Study
Cancer (Oncology) - Leukemia
Location
Swedish Cancer Institute
Short Description

Purpose: The purpose of this study is to better understand the use of tyrosine kinase inhibitors (TKI) in patients newly diagnosed with CML and their quality of life in a real-world setting.

Status
Open to Enrollment
Principal Investigator
Kenneth Kraemer, M.D.
Eligibility Notes
  • Newly-diagnosed CP-CML patients
  • Must be receiving treatment with one of the following TKI's for first-line treatment:
    • Imatinib: Retrospective Imatinib patients who started their first-line Imatinib treatment between January 2, 2008 and September 30, 2010; or patients who started their 1st line treatment on or after 10/1/2010
    • Dastinib: Patients who started their 1st line treatment after the drug was approved for this indication
    • Nilotinib: Patients who started their 1st line treatment after the drug was approved for this indication
  • Must be receiving treatment at a medical practice (e.g. community-based, office-based, hospital-based, academic setting, oncology center)
  • No patients currently participating in an interventional trial which may influence the management of their CML disease
More Info Link
Additional information about the study summary and eligibility criteria may be viewed on the U.S. National Institutes of Health (NIH) website.
Phone
(206) 215-3086
Email
CancerResearch@swedish.org